

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

U.S. PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
W	5,622,699	04/22/1997	Ruoslahti et al.	424	93.6	09/11/1995
W						

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS- LATION YES/NO
W	WO 99/46284	09/16/1999	PCT			
W	WO 99/13329	03/18/99	PCT			
W	WO 98/10795	03/19/1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

W	Antman, "Randomized Trials of High Dose Chemotherapy for Breast Cancer," <u>Biochimica et Biophysica Acta</u> 1471:M89-M98 (2001)
W	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <u>Science</u> 279:377-380 (1998)
W	Borgstrom et al., "Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin," <u>Anticancer Res.</u> 19:4203-4214 (1999).

EXAMINER 	DATE CONSIDERED 6-8-05
---	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

		Brodsky and Ramshaw, "The collagen triple-helix structure," <u>Matrix Biol.</u> 15:545-554 (1997).
ly		Brown et al., "A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library," <u>Ann. Surg. Oncol.</u> 7:743-749 (2000).
ly		Burris III, "Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Breast Cancer," <u>Semin. Oncol.</u> 28(suppl 3):38-44 (2001)
ly		Carnemolla et al., "Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix," <u>Blood</u> 99:1659-1665 (2002).
ly		Chan et al., "Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients with Metastatic Breast Cancer," <u>J. Clin. Oncol.</u> 17:2341-2354 (1999)
ly		Chen et al., "RGD-Tachyplesin Inhibits Tumor Growth," <u>Cancer Res.</u> 61:2434-2438 (2001)
ly		Crown, "The Platinum Agents: A Role in Breast Cancer Treatment?," <u>Semin. Oncol.</u> 28(suppl 3):28-37 (2001)
ly		Curnis et al., "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD 13)," <u>Nature Biotech.</u> 18:1185-1190 (2000).
ly		Dogic et al., "Extracellular matrix, integrins and focal adhesions," <u>Curr. Topics Pathol.</u> 93:75-83 (1999).
ly		Ellerby et al., "Anti-cancer activity of targeted pro-apoptotic peptides," <u>Nat. Med.</u> 5:1032-1038 (1999)


EXAMINER <i>Carfu</i>	DATE CONSIDERED 6-2-05
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

61	Engvall et al., "Nonhelical, fibronectin-binding basement-membrane collagen from endodermal cell culture," <u>Cell</u> 29:475-482 (1982).
64	Essler and Ruoslahti, "Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature," <u>Proc. Natl. Acad. Sci. USA</u> 99:2252-2257 (2002).
64	Fisher et al., "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study," <u>J. Natl. Cancer Instit.</u> 90:1371-1388 (1998)
64	Harris et al., "Cancer of the Breast", <u>Cancer: Principles and Practice of Oncology</u> , 4th Edition, Chapter 40, DeVita, Jr. et al., J.P. Lippincott: Philadelphia (1993)
64	Herbst et al., "Differential effects of laminin, intact type IV collagen, and specific domains of type IV collagen on endothelial cell adhesion and migration," <u>J. Cell Biol.</u> 106:1365-1373 (1988).
64	Hood et al., "Tumor regression by targeted gene delivery to the neovasculature," <u>Science</u> 296:2404-2407 (2002).
64	Hoppe and Reid, "Collectins - soluble proteins containing collagenous regions and lectin domains - and their roles in innate immunity," <u>Protein. Sci.</u> 3:1143-1158 (1994).
64	Jenkins and Raines, "Insights on the conformational stability of collagen," <u>Nat. Prod. Rep.</u> 19:49-59 (2002).
64	Kennel et al., "Labeling and distribution of linear peptides identified using in vivo phage-display selection for tumors," <u>Nuc. Med. Biol.</u> 27:815-825 (2000).

EXAMINER 	DATE CONSIDERED 6-8-05
---	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

Cy		Koivunen et al., "Tumor Targeting with a Selective Gelatinase Inhibitor," <u>Nat. Biotechnol.</u> 17:768-774 (1999)
Cy		Kühn, "Basement membrane (Type IV) collagen," <u>Matrix Biology</u> 14:439-445 (1994).
W		Laakkonen et al., "A tumor-homing peptide with a targeting specificity related to lymphatic vessels," <u>Nature Med.</u> 8:751-755 (2002).
ly		Marneros and Olsen, "The role of collagen-derived proteolytic fragments in angiogenesis," <u>Matrix Biology</u> 20:337-345 (2001).
Cy		Myllyharju and Kivirikko, "Collagens and collagen-related diseases," <u>Ann. Med.</u> 33:7 (2001).
W		Oku et al., "Anti-neo-vascular therapy using novel peptides homing to angiogenic vessels," <u>Oncogene</u> 21:2662-2669 (2002).
ly		Paridaens et al., "Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: a European Organization for Research and Treatment of Cancer Randomized Study with Cross-over," <u>J. Clin. Oncol.</u> 18:724-733 (2000)
ly		Pasqualini and Ruoslahti, "Organ Targeting in vivo Using Phage Display Peptide Libraries," <u>Nature</u> 380:364-366 (1996)
Cy		Porkka et al., "A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo," <u>Proc. Natl. Acad. Sci. USA</u> 99:7444-7449 (2002).
y		Rajotte et al., "Molecular Heterogeneity of the Vascular Endothelium Revealed by in Vivo Phage Display," <u>J. Clin. Invest.</u> 102:430-437 (1998)

EXAMINER 	DATE CONSIDERED 6-8-05
---	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

cy	Rasmussen et al., "Tumor cell targeting by phage-displayed peptides," <u>Cancer Gene Ther.</u> 9:606-612 (2002).
cy	Ritter et al., "Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis," <u>Proc. Natl. Acad. Sci. USA</u> 99:7455-7460 (2002).
cy	Ruoslahti and Rajotte, "An address system in the vasculature of normal tissues and tumors," <u>Annu. Rev. Immunol.</u> 18:813-827 (2000).
cy	Sado et al., "Organization and expression of basement membrane collagen IV genes and their roles in human disorders," <u>J. Biochem.</u> 123:767-776 (1998).
cy	Sidhu et al., "Phage display for selection of novel binding peptides," <u>Methods Enzym.</u> 328:333-363 (2000).
cy	Sipkins et al., "Detection of tumor angiogenesis in vivo by $\alpha V\beta 3$ -targeted magnetic resonance imaging," <u>Nature Med.</u> 4:623-626 (1998).
cy	Timpl and Brown, "Supramolecular assembly of basement membranes," <u>Bioessays</u> 18:123-132 (1996).
cy	Timpl et al., "Macromolecular organization of basement membranes," <u>Curr. Opin. Cell Biol.</u> 8:618-624 (1996).
cy	Tsai, "Stuck on the ECM," <u>Trends Cell Biol.</u> 8:292-295 (1998).
cy	Vicini et al., "Accelerated Treatment of Breast Cancer," <u>Journal of Clinical Oncology</u> 19:1993-2001 (2001).
cy	White et al., "Antibody-Targeted Immunotherapy for Treatment of Malignancy," <u>Annu. Rev. Med.</u> 52:125-145 (2001)

EXAMINER <i>Cyfe</i>	DATE CONSIDERED <i>6-8-05</i>
-------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66821-233	SERIAL NO. 10/648,813
	APPLICANT: Ruoslahti et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 25, 2003	GROUP: Unassigned

W		Wolff, "Systemic Therapy," <u>Curr. Opin. Oncology</u> 12:532-540 (2000)
W		Xu et al., "Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo," <u>J. Cell Biol.</u> 154:1069-1079 (2001).
W		Yoshikawa et al., "Secretion of non-helical collagenous polypeptides of $\alpha 1$ (IV) and $\alpha 2$ (IV) chains upon depletion of ascorbate by cultured human cells," <u>J. Biochem.</u> 129:929-936 (2001).
W		GenBank Accession No. XP_159359
W		GenBank Accession No. XP_166493
W		GenBank Accession No. NP_493955

EXAMINER <i>C. J.</i>	DATE CONSIDERED <i>6-8-05</i>
--------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.